EU biotech firms unite in pushing for ‘harmonised’ microbiome therapeutics regulation

Posted by: | June 6, 2019 | Comments

EU biotech firms unite in pushing for 'harmonised' microbiome therapeutics regulation

The Intestinal Microbiome-based Medicines European Task Group (IMM-ETG) involves Caelus Health, EnteroBiotix, Ferring Pharmaceuticals and Maat Pharma along with Pharmabiotic Research Institute (PRI).

“The IMM-ETG has been established to contribute to a harmonised regulatory framework in Europe for the intestinal microbiome products based on the whole ecosystem,” said Dr. Luc Sterkman, CEO of Caelus Health.

“In addition, we would like to obtain a universally accepted product classification of these products.

“In the process of achieving these two initial objectives, the IMM-ETG aims to interact with key stakeholders and to facilitate close and open communication with academic groups, clinicians and last but not least regulatory bodies.”

Read more at Nutraingredients






Stay up-to-date!
Email Address *
First Name
Last Name

* indicates required
Privacy Policy




Terms & Conditions | Privacy Policy | © 2019 The Translational Microbiome Research Forum